Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $9.33

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has received a consensus rating of “Hold” from the ten ratings firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $9.33.

A number of brokerages recently commented on FULC. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. HC Wainwright reiterated a “neutral” rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th.

Institutional Trading of Fulcrum Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in FULC. Charles Schwab Investment Management Inc. increased its holdings in shares of Fulcrum Therapeutics by 223.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 569,185 shares of the company’s stock worth $2,032,000 after purchasing an additional 393,202 shares during the period. State Street Corp grew its position in Fulcrum Therapeutics by 61.4% during the third quarter. State Street Corp now owns 1,680,229 shares of the company’s stock worth $5,998,000 after buying an additional 638,955 shares in the last quarter. Braidwell LP bought a new position in Fulcrum Therapeutics in the 3rd quarter worth about $3,817,000. Barclays PLC raised its holdings in shares of Fulcrum Therapeutics by 367.1% in the 3rd quarter. Barclays PLC now owns 124,141 shares of the company’s stock valued at $443,000 after acquiring an additional 97,565 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Fulcrum Therapeutics during the 3rd quarter valued at about $474,000. 89.83% of the stock is currently owned by institutional investors.

Fulcrum Therapeutics Trading Down 2.5 %

Shares of NASDAQ FULC opened at $4.37 on Thursday. The stock’s 50 day simple moving average is $3.99 and its 200 day simple moving average is $5.53. The company has a market cap of $235.71 million, a price-to-earnings ratio of -14.10 and a beta of 2.06. Fulcrum Therapeutics has a 12-month low of $2.86 and a 12-month high of $13.70.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.